Old Second National Bank Of Aurora Lowers stake in Pfizer (PFE)

Pfizer (PFE) : Old Second National Bank Of Aurora reduced its stake in Pfizer by 35.31% during the most recent quarter end. The investment management company now holds a total of 18,036 shares of Pfizer which is valued at $600,058 after selling 9,844 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.Pfizer makes up approximately 0.28% of Old Second National Bank Of Aurora’s portfolio.

Pfizer closed down -0.05 points or -0.15% at $33 with 2,60,94,478 shares getting traded on Wednesday. Post opening the session at $32.98, the shares hit an intraday low of $32.9 and an intraday high of $33.21 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Other Hedge Funds, Including , Meritage Portfolio Management boosted its stake in PFE in the latest quarter, The investment management firm added 56,010 additional shares and now holds a total of 158,213 shares of Pfizer which is valued at $5,263,747. Pfizer makes up approx 0.59% of Meritage Portfolio Management’s portfolio.Boltwood Capital Management reduced its stake in PFE by selling 10,675 shares or 3.27% in the most recent quarter. The Hedge Fund company now holds 315,903 shares of PFE which is valued at $10,266,848. Pfizer makes up approx 8.90% of Boltwood Capital Management’s portfolio.Searle boosted its stake in PFE in the latest quarter, The investment management firm added 2,620 additional shares and now holds a total of 35,150 shares of Pfizer which is valued at $1,142,375. Pfizer makes up approx 1.04% of Searle’s portfolio.Atalanta Sosnoff Capital reduced its stake in PFE by selling 574,896 shares or 29.7% in the most recent quarter. The Hedge Fund company now holds 1,360,598 shares of PFE which is valued at $44,219,435. Pfizer makes up approx 1.38% of Atalanta Sosnoff Capital’s portfolio.

On the company’s financial health, Pfizer reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.36. The company had revenue of $14047.00 million for the quarter, compared to analysts expectations of $13595.19 million. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.

Many Wall Street Analysts have commented on Pfizer. Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.Morgan Stanley Resumed Pfizer on Apr 7, 2016 to “Equal-Weight”, Price Target of the shares are set at $35.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.